Search research articles
Contact Us
Filters
Showing results (161-170 of 173) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve <i>EGFR</i>-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)
Xiuning Le, Jyoti D Patel, Elaine Shum, et al.
The New England Journal of Medicine
|
October 23, 2023
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions
Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, et al.
Nature Medicine
|
June 13, 2024
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, et al.
Signal Transduction and Targeted Therapy
|
June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.
Targeted Oncology
|
November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park, Eric B Haura, Natasha B Leighl, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
Mariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Benjamin Besse, Koichi Goto, Yongsheng Wang, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 173) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve <i>EGFR</i>-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)
Xiuning Le, Jyoti D Patel, Elaine Shum, et al.
The New England Journal of Medicine
|
October 23, 2023
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions
Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, et al.
Nature Medicine
|
June 13, 2024
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, et al.
Signal Transduction and Targeted Therapy
|
June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.
Targeted Oncology
|
November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park, Eric B Haura, Natasha B Leighl, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
Mariam Alexander, Ying Cheng, Se-Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Benjamin Besse, Koichi Goto, Yongsheng Wang, et al.
Page
of 18